Literature DB >> 12672453

Substrate access and processing by the 20S proteasome core particle.

Michael Groll1, Robert Huber.   

Abstract

Intracellular proteolysis is an essential process. In eukaryotes, most proteins in the cytosol and nucleus are degraded by the ubiquitin (Ub)-proteasome pathway. A major component within this system is the 26S proteasome, a 2.5MDa molecular machine, built from more than 31 different subunits. This complex is formed by a cylinder-shaped multimeric complex referred to as the proteolytic 20S proteasome (core particle, CP) capped at each end by another multimeric component called the 19S complex (regulatory particle, RP) or PA700. Structure, assembly and enzymatic mechanism have been elucidated only for the CP, whereas the organization of the RP is less well understood. The CP is composed of 28 subunits, which are arranged as an alpha7beta7beta7alpha7-complex in four stacked rings. The interior of the free core particle, which harbors the active sites, is inaccessible for folded and unfolded substrates and represents a latent state. This inhibition is relieved upon binding of the RP to the CP by formation of the 26S proteasome holoenzyme. This review summarizes the current knowledge of the structural features of 20S proteasomes.

Mesh:

Substances:

Year:  2003        PMID: 12672453     DOI: 10.1016/s1357-2725(02)00390-4

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  60 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  Rearrangement of the 16S precursor subunits is essential for the formation of the active 20S proteasome.

Authors:  Srinivas Mullapudi; Lee Pullan; Ozlem T Bishop; Hassan Khalil; James K Stoops; Roland Beckmann; Peter M Kloetzel; Elke Krüger; Pawel A Penczek
Journal:  Biophys J       Date:  2004-09-10       Impact factor: 4.033

3.  Mdm2 facilitates the association of p53 with the proteasome.

Authors:  Roman Kulikov; Justine Letienne; Manjit Kaur; Steven R Grossman; Janine Arts; Christine Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

4.  Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome.

Authors:  Theresa A Lansdell; Nicole M Hewlett; Amanda P Skoumbourdis; Matthew D Fodor; Ian B Seiple; Shun Su; Phil S Baran; Ken S Feldman; Jetze J Tepe
Journal:  J Nat Prod       Date:  2012-05-16       Impact factor: 4.050

Review 5.  The ubiquitin-proteasome pathway and plant development.

Authors:  Jennifer Moon; Geraint Parry; Mark Estelle
Journal:  Plant Cell       Date:  2004-12       Impact factor: 11.277

6.  A mathematical model of protein degradation by the proteasome.

Authors:  Fabio Luciani; Can Keşmir; Michele Mishto; Michal Or-Guil; Rob J de Boer
Journal:  Biophys J       Date:  2005-01-21       Impact factor: 4.033

7.  Electrospray ionization mass spectrometry and ion mobility analysis of the 20S proteasome complex.

Authors:  Joseph A Loo; Beniam Berhane; Catherine S Kaddis; Kerry M Wooding; Yongming Xie; Stanley L Kaufman; Igor V Chernushevich
Journal:  J Am Soc Mass Spectrom       Date:  2005-07       Impact factor: 3.109

Review 8.  The ubiquitin-proteasome system in myocardial ischaemia and preconditioning.

Authors:  Saul R Powell; Andras Divald
Journal:  Cardiovasc Res       Date:  2009-09-30       Impact factor: 10.787

9.  Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry.

Authors:  David M Smith; Shih-Chung Chang; Soyeon Park; Daniel Finley; Yifan Cheng; Alfred L Goldberg
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

Review 10.  The ubiquitin proteasome system and myocardial ischemia.

Authors:  Justine Calise; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-07       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.